Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based pharmaceutical company R-Tech Ueno has selected Novozymes Biopharma's recombinant human albumin Albucult for dry eye syndrome treatment.
Subscribe to our email newsletter
R-Tech Ueno will use Albucult as a major component in its new therapy to treat severe and moderate dry eye conditions.
Albucult is believed to confer many advantages to the development of R-Tech Ueno’s new therapy in terms of purity profile and batch-to-batch consistency.
In addition, the use of the recombinant human albumin can also help to optimize pathways through regulatory approval procedures and improve time-to-market.
Albucult is manufactured by Novozymes’ technology partner Kaketsuken based in Kumamoto, Japan and marketed by Novozymes across the globe.